Paul Scherrer Institute

About: Paul Scherrer Institute is a facility organization based out in Villigen, Switzerland. It is known for research contribution in the topics: Neutron & Large Hadron Collider. The organization has 9248 authors who have published 23984 publications receiving 890129 citations. The organization is also known as: PSI.

Toward clinical X-ray phase-contrast CT: demonstration of enhanced soft-tissue contrast in human specimen.

Abstract: X-ray computed tomography (CT) using phase contrast can provide images with greatly enhanced soft-tissue contrast in comparison to conventional attenuation-based CT. We report on the first scan of a human specimen recorded with a phase-contrast CT system based on an x-ray grating interferometer and a conventional x-ray tube source. Feasibility and potential applications of preclinical and clinical phase-contrast CT are discussed.

Search for massive resonances in dijet systems containing jets tagged as W or Z boson decays in pp collisions at sqrt(s) = 8 TeV

Abstract: A search is reported for massive resonances decaying into a quark and a vector boson (W or Z), or two vector bosons (WW, WZ, or ZZ). The analysis is performed on an inclusive sample of multijet events corresponding to an integrated luminosity of 19.7 inverse femtobarns, collected in proton-proton collisions at a centre-of-mass energy of 8 TeV with the CMS detector at the LHC. The search uses novel jet-substructure identification techniques that provide sensitivity to the presence of highly boosted vector bosons decaying into a pair of quarks. Exclusion limits are set at a confidence level of 95% on the production of: (i) excited quark resonances q* decaying to qW and qZ for masses less than 3.2 TeV and 2.9 TeV, respectively, (ii) a Randall-Sundrum graviton G[RS] decaying into WW for masses below 1.2 TeV, and (iii) a heavy partner of the W boson W' decaying into WZ for masses less than 1.7 TeV. For the first time mass limits are set on W' to WZ and G[RS] to WW in the all-jets final state. The mass limits on q* to qW, q* to qZ, W' to WZ, G[RS] to WW are the most stringent to date. A model with a "bulk" graviton G[Bulk] that decays into WW or ZZ bosons is also studied.

Eddy covariance flux measurements of biogenic VOCs during ECHO 2003 using proton transfer reaction mass spectrometry

Abstract: . Within the framework of the AFO 2000 project ECHO, two PTR-MS instruments were operated in combination with sonic anemometers to determine biogenic VOC fluxes from a mixed deciduous forest site in North-Western Germany. The measurement site was characterised by a forest of inhomogeneous composition, complex canopy structure, limited extension in certain wind directions and frequent calm wind conditions during night time. The eddy covariance (EC) technique was applied since it represents the most direct flux measurement approach on the canopy scale and is, therefore, least susceptible to these non-ideal conditions. A specific flux calculation method was used to account for the sequential multi-component PTR-MS measurements and allowing an individual delay time adjustment as well as a rigorous quality control based on cospectral analysis. The validated flux results are consistent with light and temperature dependent emissions of isoprene and monoterpenes from this forest, with average daytime emissions of 0.94 and 0.3µg m-2s-1, respectively. Emissions of methanol reached on average 0.087µg m-2s-1 during daytime, but fluxes were too small to be detected during night time. Upward fluxes of the isoprene oxidation products methyl vinyl ketone (MVK) and methacrolein (MACR) were also found, being two orders of magnitude lower than those of isoprene. Calculations with an analytical footprint model indicate that the observed isoprene fluxes correlate with the fraction of oaks within the footprints of the flux measurement.

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Abstract: Objective: To assess the relationship between striatal dopa decarboxylase capacity, D2dopamine receptor binding, and energy metabolism in Parkinson's disease (PD). Design: Positron emission tomographic (PET) studies of glucose and dopa metabolism and D2dopamine receptor binding in the caudate nucleus and putamen of patients with PD at different Hoehn and Yahr (HY) stages using PET and the tracers18F-fluorodeoxyglucose (FDG), 6-18F-fluoro-l-dopa (FDOPA), and11C-raclopride (RACLO). Setting: Positron emission tomography research program at the Paul Scherrer Institute. Subjects: Twenty patients with PD at different stages of the disease (HY stages I through IV; five patients for each stage) compared with separate groups of agematched healthy subjects. Main Outcome Measures: Influx constant ( Ki ) for specific FDOPA uptake; uptake index ratio for RACLO binding to D2dopamine receptors; normalized to global FDG metabolic rate for glucose consumption; and semiquantitative score for assessment of tremor, rigidity, and bradykinesia in PD. Results: Patients with PD at HY stages I to II (hereafter HY-I-II PD) revealed reduced FDOPA metabolism, particularly in the putamen. The FDOPA uptake in the putamen and caudate nucleus declined with increasing HY staging and scoring for bradykinesia and rigidity. Putamen RACLO binding to D2dopamine receptors was up-regulated in patients with HY-I-II PD but declined toward control values, with increasing disease severity. Putamen side-to-side asymmetries of FDOPA metabolism and RACLO binding revealed a significant correlation. Putamen FDG metabolism showed a relative increase in all patients with PD. Conclusions: Our results show that FDOPA, RACLO, and FDG PET measurements provide complementary information to characterize metabolic and receptor changes in the striatum of PD with different degrees of motor disability. The FDOPA uptake reflects the best motorrelated pathologic features, as indicated by the significant correlation betweenKivalues and clinical scores. The significant association between RACLO and FDOPA in the putamen suggests that D2dopamine receptor changes are related to the reduction of presynaptic dopaminergic nerve terminals. Putamen FDG increase is probably the result of more complex feedback mechanisms that are primarily induced by striatal dopamine deficiency.